| abstract |
The present invention relates to novel compounds that are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), pharmaceutical compositions containing them, methods for their production, and are not limited But obesity, obesity-related disorders, hereditary (type 1, type 5 hyperlipidemia) and, but not limited to, lipodystrophy, hypothyroidism, medication (beta blockers, thiazides, estrogens , Glucocorticoids, grafts) and other factors (pregnancy, alcohol consumption) acquired hypertriglyceridemia or hyperlipoproteinemia related disorders, hyperlipoproteinemia, chylomicronemia, dyslipidemia Disease, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcome, angina, hirsutism (for hirsutism) Associated with DGAT-1 dysfunction or including DGAT-1 dysfunction, including nephrotic syndrome, fibrosis such as myocardium, kidney and liver fibrosis, hepatitis C virus infection and acne or other skin disorders 1 relates to their use alone or in combination with weight management therapy or other triglyceride lowering therapy in therapies for the prevention or treatment of diseases where modulation of activity may have therapeutic benefit. |